Sperm DNA fragmentation testing: Summary evidence and clinical practice recommendations
- PMID: 33108829
- PMCID: PMC7988559
- DOI: 10.1111/and.13874
Sperm DNA fragmentation testing: Summary evidence and clinical practice recommendations
Abstract
We herein summarise the evidence concerning the impact of sperm DNA fragmentation in various clinical infertility scenarios and the advances on sperm DNA fragmentation tests. The collected evidence was used to formulate 41 recommendations. Of these, 13 recommendations concern technical aspects of sperm DNA fragmentation testing, including pre-analytical information, clinical thresholds and interpretation of results. The remaining 28 recommendations relate to indications for sperm DNA fragmentation testing and clinical management. Clinical scenarios like varicocele, unexplained infertility, idiopathic infertility, recurrent pregnancy loss, intrauterine insemination, in vitro fertilisation/intracytoplasmic sperm injection, fertility counselling for men with infertility risk factors and sperm cryopreservation have been contemplated. The bulk evidence supporting the recommendations has increased in recent years, but it is still of moderate to low quality. This guideline provides clinicians with advice on best practices in sperm DNA fragmentation testing. Also, recommendations are provided on possible management strategies to overcome infertility related to sperm DNA fragmentation, based on the best available evidence. Lastly, we identified gaps in knowledge and opportunities for research and elaborated a list of recommendations to stimulate further investigation.
Keywords: assisted reproductive technology; male infertility; practice guideline; semen analysis; sperm DNA fragmentation.
© 2020 The Authors. Andrologia published by Wiley-VCH GmbH.
Conflict of interest statement
SCE declares the receipt of unrestricted research grants and lecture fees from Merck outside the submitted work. PH reports receipt of unrestricted research grants from Merck, IBSA, Gedeon Richter, and MSD, and lecture fees from Merck, Gedeon Richter, MSD, and IBSA outside the submitted work. AZ declares shares in YAD‐Tech neutraceuticals. DPE is president director of SCSA Diagnostics, a company with a commercial interest in sperm DNA damage. SEML is an employee of Examenlab Ltd., a university spin‐out company with a commercial interest in sperm DNA damage. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Figures
References
-
- Abdelbaki, S. A. , Sabry, J. H. , Al‐Adl, A. M. , & Sabry, H. H. (2017). The impact of coexisting sperm DNA fragmentation and seminal oxidative stress on the outcome of varicocelectomy in infertile patients: A prospective controlled study. Arab Journal of Urology, 15, 131–139. 10.1016/j.aju.2017.03.002 - DOI - PMC - PubMed
-
- Aboulmaouahib, S. , Madkour, A. , Kaarouch, I. , Sefrioui, O. , Saadani, B. , Copin, H. , Benkhalifa, M. , Louanjli, N. , & Cadi, R. (2018). Impact of alcohol and cigarette smoking consumption in male fertility potential: Looks at lipid peroxidation, enzymatic antioxidant activities and sperm DNA damage. Andrologia, 50(3), e12926. 10.1111/and.12926 - DOI - PubMed
-
- Agarwal, A. , Gupta, S. , Du Plessis, S. , Sharma, R. , Esteves, S. C. , Cirenza, C. , Eliwa, J. , Al‐Najjar, W. , Kumaresan, D. , Haroun, N. , Philby, S. , & Sabanegh, E. (2016). Abstinence time and its impact on basic and advanced semen parameters. Urology, 94, 102–110. 10.1016/j.urology.2016.03.059 - DOI - PubMed
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
